- Conditions
- Atherosclerosis
- Interventions
- Statin therapy, Lifestyle modification
- Drug · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
- Interventions
- Percutaneous mitral valve repair using MitraClip implant
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Indianapolis, Indiana
- Conditions
- Multiple Myeloma
- Interventions
- myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
- Device · Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Lymphoma
- Interventions
- recombinant interferon alfa, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, fludarabine phosphate, Total body irradiation, Umbilical cord blood unit with C3a fragment, Unmanipulated UCB Unit
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure, Hyperkalemia
- Interventions
- Not listed
- Lead sponsor
- Vifor (International) Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • La Jolla, California • Northridge, California + 46 more
- Conditions
- Plaque, Atherosclerotic Disease, Heart Disease, Stroke
- Interventions
- Not listed
- Lead sponsor
- BG Medicine, Inc
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 7,687 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Oakland Park, Florida • Justice, Illinois
- Conditions
- Hypertension, Elevated Cholesterol, Overweight and Obesity
- Interventions
- Dietary Intervention
- Other
- Lead sponsor
- Texas Woman's University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Artery Disease, Heart Disease, Coronary Arteriosclerosis, Cardiovascular Disease, Myocardial Ischemia
- Interventions
- Not listed
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 824 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Anaheim, California • Escondido, California + 35 more
- Conditions
- Cardiovascular Risk Factor, Lipemia
- Interventions
- High-fat meal
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Heart Failure, Diabetes
- Interventions
- Message with EchoGo, Standard Message
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Myelodysplastic Syndrome, Philadelphia Chromosome-negative CML, Myeloid Metaplasia, Myelofibrosis, Advanced Polycythemia, Non-Hodgkins Lymphoma
- Interventions
- TAK-901
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes, High Blood Pressure
- Interventions
- Polypill, Combined prescription of the individual medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
- Interventions
- Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO)
- Device
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Morristown, New Jersey
- Conditions
- ASCVD, Hyperlipidemia, Hypertension
- Interventions
- Referral to the Duke Cardiometabolic Prevention Clinic
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- Assessment of platelet reactivity, Troponin measurement
- Diagnostic Test
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Stroke, Transient Ischemic Attack (TIA)
- Interventions
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Genetic
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hypertension
- Interventions
- Dietary and physical activity JITAI delivered through the myBPmyLife app, Control Group
- Behavioral · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Flint, Michigan
- Conditions
- Multiple Myeloma, Primary Amyloidosis
- Interventions
- Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Diseases
- Interventions
- Medication Adherence System (MAS), Usual Care
- Behavioral
- Lead sponsor
- PHCC LP
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Pueblo, Colorado
- Conditions
- Peripheral Artery Disease, Critical Limb Ischemia, Claudication
- Interventions
- standard gauze dressing, Prevena Incision Management system
- Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
- Conditions
- Cardiovascular Disease
- Interventions
- bococizumab (PF-04950615), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 518
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas